Posted by Michael Wonder on 27 Dec 2024
Datroway approved in Japan as the first TROP-2 directed therapy for patients with previously treated unresectable or recurrent hormone receptor positive, HER2 negative breast cancer
27 December 2024 - First global approval based on TROPION-Breast01 where Datroway significantly reduced the risk of disease progression or death by 37% versus chemotherapy.
Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.
